Suppr超能文献

I(1)咪唑啉/α(2)-肾上腺素能受体激动剂莫索尼定与可乐定在大鼠福尔马林试验中的作用比较

Effects of the I(1) imidazoline/alpha(2)-adrenergic receptor agonist moxonidine in comparison with clonidine in the formalin test in rats.

作者信息

Shannon H E, Lutz E A

机构信息

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, USA.

出版信息

Pain. 2000 Mar;85(1-2):161-7. doi: 10.1016/s0304-3959(99)00260-2.

Abstract

Moxonidine is a mixed I(1) imidazoline/alpha(2)moxonidine=morphine. The I(1) imidazoline preferring antagonist efaroxan produced a dose-dependent antagonism of both moxonidine (5.0 mg/kg) and clonidine (0.5 mg/kg). In addition, the alpha(2)-adrenergic receptor antagonist yohimbine produced a dose-related antagonism of moxonidine, but only partially antagonized clonidine. Prazosin failed to block the effects of either moxonidine or clonidine, indicating a lack of involvement of alpha(1) as well as alpha(2B) and alpha(2C) receptors. The present results suggest that alpha(2)-adrenergic receptors play an important role in mediating the effects of moxonidine in producing antinociception in the formalin test. Further, the present results demonstrate that the mechanism of action of moxonidine and clonidine differ in that clonidine, but not moxonidine, produces an antinociceptive effect through a yohimbine-insensitive mechanism in the formalin test.

摘要

莫索尼定是一种混合型 I(1) 咪唑啉/α(2) 肾上腺素能受体激动剂,其抗伤害感受作用类似于吗啡。选择性 I(1) 咪唑啉拮抗剂依酚氯铵对莫索尼定(5.0 毫克/千克)和可乐定(0.5 毫克/千克)均产生剂量依赖性拮抗作用。此外,α(2) 肾上腺素能受体拮抗剂育亨宾对莫索尼定产生剂量相关的拮抗作用,但仅部分拮抗可乐定。哌唑嗪未能阻断莫索尼定或可乐定的作用,表明α(1) 以及α(2B) 和α(2C) 受体未参与其中。目前的结果表明,α(2) 肾上腺素能受体在介导莫索尼定在福尔马林试验中产生抗伤害感受作用方面发挥重要作用。此外,目前的结果表明,莫索尼定和可乐定的作用机制不同,因为在福尔马林试验中,可乐定通过一种育亨宾不敏感的机制产生抗伤害感受作用,而莫索尼定则不然。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验